Table 4.
Summary of studies comparing plasma total homocysteine levels in patients with subclinical hypothyroidism and control subjects.
| Number of patients and controls | Total homocysteine (μmol/L) | ||||
|---|---|---|---|---|---|
| Reference | Total (F:M) | Control | Patients | Control | P value |
|
| |||||
| Lindeman et al38 | 93 (61:32) | 643 (283:360) | 12.8±4.1 | 12.5±3.7 | 0.12 |
| 19 (13:6) | 643 (283:360) | 11.7±2.6 | 12.5±3.7 | 0.429 | |
|
| |||||
| Luboshitzky et al34 | 57 F | 34 F | 9.0±2.5 | 9.2±2.6 | NS |
|
| |||||
| Christ-Crain et al29 | 63 F | 40 F | 11.3±2.8 | 11.0±2.7 | NS |
|
| |||||
| Aldasouqui et al42 | 47 (42:5) | 50 (46:4) | 7.44±0.5 | 7.22±0.2 | 0.68 |
|
| |||||
| Meek et al40 | 12 (7:5) † | § | 10 (5–37)** | § | § |
| 12 (10:2) ‡ | § | 8 (6–15)** | § | § | |
|
| |||||
| Deicher & Vierhapper39 | 37 (31:6) | § | 9.9±2.9 | § | § |
|
| |||||
| Current study | 53 (47:6) | 50 (47:3) | 9.6±3.1 | 10.3±3.4 | 0.29 |
*
Mean±SD,
**
Median (range),
†
Levothyroxine group (baseline measurements),
‡
Placebo group(baseline measurements),
§
No control subjects,
NS, No significant difference; F, Female; M, Male.